Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.
Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.
复制标题
戈利木单抗用于治疗既往 TNF-α 治疗失败患者的化脓性汗腺炎。
DOI：
10.1016/j.jid.2021.04.026
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Sayed,Christopher
中科院分区：
文献类型：
--
作者：
Melendez-Gonzalez,MariaDelMar;Hamad,Judy;Sayed,Christopher
化脓性汗腺炎 (HS) 是一种慢性皮肤炎症性疾病，表现为反复出现炎症结节、囊肿、脓肿、窦道和疤痕形成。通常需要结合药物和手术治疗。阿达木单抗是美国食品和药物管理局唯一批准的治疗 HS 的药物，它是一种靶向 TNF-α 的单克隆抗体（Alikhan 等人，2019a、2019b；Kimball 等人，2016）。戈利木单抗（另一种完全人源化 TNF-α 抑制剂）的使用已在两例 HS 病例中得到描述，结果好坏参半（Tursi，2016 年；van der Zee 和 Prens，2013 年）。早期的体内和体外研究表明，戈利木单抗对跨膜和可溶性 TNF-α 受体的亲和力比阿达木单抗和英夫利昔单抗更高，表明它是一种潜在的治疗选择（Cunningham 等，2019；Flamant 等，2017；Shealy 等，2010）。这项回顾性队列研究得到了北卡罗来纳大学教堂分校机构审查委员会的批准 爬坡道。通过电子病历中的临床跟踪列表来识别接受戈利木单抗治疗 HS 的患者。 2018 年 3 月至 2020 年 8 月收集的数据包括人口统计数据和临床数据，包括戈利木单抗治疗史。纳入标准要求戈利木单抗治疗至少 10 周，剂量为 2 mg/kg 或 200 mg 较高者，通常在第 0 周、第 2 周和每 4 周进行一次。通过筛选代表性队列并建立明确的数据收集变量来解决选择和信息偏差。
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin presenting with recurrent inflammatory nodules, cysts, abscesses, sinus tracts, and scar formation. Combined medical and surgical management is often required. The only Food and Drug Administration‒approved treatment for HS, adalimumab, is a mAb targeting TNF-α (Alikhan et al., 2019a, 2019b; Kimball et al., 2016). The use of golimumab, another fully humanized TNF-α inhibitor, has been described in two cases of HS with mixed results (Tursi, 2016; van der Zee and Prens, 2013). Early in vivo and in vitro studies showed that golimumab has a higher affinity for transmembrane and soluble TNF-α receptors than adalimumab and infliximab, suggesting it as a potential treatment option (Cunningham et al., 2019; Flamant et al., 2017; Shealy et al., 2010).This retrospective cohort study was approved by the Institutional Review Board at the University of North Carolina Chapel Hill. Patients treated with golimumab for HS were identified through clinical tracking lists in the electronic medical record. Data collected from March 2018 to August 2020 included demographics and clinical data, including golimumab treatment history. Inclusion criteria required a minimum of 10 weeks of golimumab treatment at a dose of the higher of either 2 mg/kg or 200 mg, typically at week 0, week 2, and every 4 weeks. Selection and information biases were addressed by screening for a representative cohort and by establishing clear variables for data collection.